期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Background Bevacizumab, an inhibitor of angiogenesis, has been approved in several anti-cancer therapies. This study compared the pharmacokinetic (PK)......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Objectives: The study aimed to explore the bioequivalence of a proposed biosimilar HL02 vs. its reference products (US-trastuzumab) among healthy Chin......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Background: Humira (R) is a fully humanized anti-tumor necrosis factor (TNF-alpha) monoclonal antibody that has been marketed and approved in the Unit......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (10)
Introduction Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors mobilize and activate the anti-tumor activity of the immune system b......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (7)
Introduction Atopic dermatitis (AD) is a common chronic recurrent inflammatory skin disease. The pathogenesis is unclear but may be related to genetic......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Background This study was conducted to compare the similarity of the pharmacokinetics (PKs), safety, and immunogenicity of GB222, a potential bevacizu......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (2)
Background: Perjeta (R) is a recombinant, humanized monoclonal antibody that has been marketed and approved for the targeted therapy of human epiderma......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2022; 22 (7)
Introduction Tissue engineering has brought hope for the repair of bone and cartilage injury. As potential therapeutic molecules for use in tissue eng......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, ; ()
Objectives: The study aimed to explore the bioequivalence of a proposed biosimilar HL02 vs. its reference products (US-trastuzumab) among healthy Chin......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, ; ()
Introduction: Although viruses have generally been considered as pathogens ever since their discovery, recent research has revealed that they might as......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2020; 20 (3)
Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whe......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2020; 20 (6)
Introduction: Immunotherapy is now a standard treatment for many malignancies. Although immune checkpoint inhibition has demonstrated substantial effi......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2020; 20 (7)
Introduction: RNA-based cancer gene therapy shows potential in cancer treatment. However, the safe and efficient transfer of therapeutic RNA to target......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2020; 20 (8)
Introduction: Immune therapies have dramatically changed the treatment landscape for melanoma in the past decade. Ipilimumab, nivolumab, and pembroliz......
期刊： EXPERT OPINION ON BIOLOGICAL THERAPY, 2020; 20 (11)
Introduction Chimeric antigen receptor T (CAR-T) cells are harnessed to identify and lyse malignant cells specifically, efficiently, and independently......
